A guide to the choices that shape evidence, access, and adoption.
Deciding What Value Matters, to Whom, and How You'll Prove It
A guide to the choices that shape evidence, access and adoption.
A value story explains why a therapy matters, who benefits, and why it deserves coverage.
It brings clinical, economic, and humanistic evidence together into one clear argument. The strongest value stories go beyond the basic requirements to the differentiated value a therapy can claim.
Meet the requirements, then lead with differentiated value.
Value is always relative: to a comparator, a stakeholder, and a decision.
Keep one story. Adjust the emphasis for each audience, never the facts.
Start in Phase 1. Early trial choices decide what you can claim at launch.
In health care, value is not a fixed property of a therapy. It is a judgment someone makes, and it has three features.
Value is measured against an alternative, usually current standard of care. The choice of comparator shapes every claim.
A clinician, a payer, an HTA body, and a patient can weigh the same evidence differently.
A formulary listing, an HTA recommendation, and a prescribing choice each use different criteria.
What is difficult, costly, or inadequate about current standard of care for patients, caregivers, clinicians, and health systems?
How could the therapy improve outcomes or the treatment experience compared with relevant alternatives?
How might the therapy affect health care use, total cost of care, budget impact, or cost-effectiveness?
What benefit does treatment bring to people's lives beyond survival or disease control? Quality of life, daily functioning, symptom and treatment burden, and caregiver well-being.
A therapy rarely wins on all four. Choosing which ones the case will rest on, and where the therapy is truly different, is the first job of the value story.
A value story turns a broad sense that a therapy is valuable into specific choices.
Every story must first meet the requirements: the evidence any decision-maker expects to see, such as efficacy, safety, and burden of disease. On top of that sits differentiated value: the benefits that set the therapy apart from the alternatives. Value a competitor can also claim rarely earns access or a premium on its own.
Whose judgment determines access and use: a US payer, a European HTA body, prescribers, patients?
What exactly is being decided, when, and on what criteria?
Which evidence will that decision-maker accept, and does it exist yet or does it still need to be generated?
Until these four questions have answers, most downstream decisions are guesses.
The value story sits at the top and guides evidence, access, and communication. The relationship runs both ways: new evidence can also reshape the value story.
Requirements, differentiated value, priority stakeholders, decisions, and the proof each one requires
Endpoints, comparators, patient-reported outcomes, real-world studies, economic models
Payer engagement, pricing, HTA submissions, contracting
Value dossier, payer presentations, objection handlers, publications
The value story tells the evidence team what to prove. As results come in, the evidence may strengthen, narrow, or redirect the story.
A dossier can be comprehensive, rigorous, and expensive and still answer the wrong questions if the value story above it is unclear.
With a clear value story, downstream questions have better answers.
The one where value is most believable.
The one the payer will use.
The ones that matter in the decision.
The one that supports the value claim.
Many of these choices are made during clinical development. The comparator, endpoints, patient-reported outcome measures, subgroups, and follow-up period all affect what the company can claim later. Each is a value story decision, whether or not anyone treats it as one.
An early value story is a hypothesis. It shows which claims are already supported, which need testing with payers or other stakeholders, and which need additional evidence.
The story becomes more specific as the evidence matures.
A useful value story informs trial design, evidence generation, pricing research, payer engagement, publication planning, and launch materials. It also gives clinical, medical, HEOR, market access, and commercial teams a common standard for evaluating new work.
Which part of the value case will this strengthen, and which future decision will it support?
Does this endpoint answer a question the decision-maker will ask?
Does this publication support a claim in the value case?
Does this model reflect the decision the payer is making?
Are we engaging the right stakeholders?
Are our messages consistent with the evidence behind them?
In written form, the value story is a concise, evidence-based explanation of the value a therapy may deliver relative to current standard of care. It turns disparate findings from clinical trials, economic analyses, real-world studies, and patient research into a logical case.
A value story should help a decision-maker understand the problem the therapy addresses, how it changes outcomes, and why that change matters. It should also be honest about uncertainty and the evidence still needed.
The evidence base should remain consistent, but different audiences use it to make different decisions. Clinicians focus on effectiveness, safety, and fit within care. US payers consider comparative benefit, budget impact, and the conditions for coverage.
HTA bodies assess comparative effectiveness and, in many markets, value for money. Patients and advocates focus on outcomes and humanistic burdens that shape daily life.
Adapting the emphasis is useful. Changing the facts or allowing each function to create a separate story creates confusion and weakens credibility.
No. The value story defines the argument. Access strategy decides how to use that argument to win specific coverage, pricing, and HTA decisions.
The value story is the strategic argument: the case for why your drug deserves coverage at a specific price. The value dossier is one vehicle for delivering that argument.
Think of the value story as the legal brief and the dossier as one of the courtroom filings. You need the argument before you need the filing.
Start now. Early data is enough to form hypotheses about where value will be differentiated, identify likely comparators, and build exploratory models. Revisit the story at each readout. The most important step is planning your pivotal trial, whether that is Phase 2 or Phase 3, because it determines what you can claim at launch.
You're building the blueprint, not the building.
At each major evidence milestone: each early-phase readout, finalization of the pivotal trial protocol (Phase 2 or Phase 3), and topline pivotal results. Also revisit it when the external picture shifts: a new competitor, a change in standard of care, or new payer or HTA requirements.
Each review should ask whether the four core choices still hold and whether the evidence plan still supports them.
A value story is a working hypothesis.
It should change when the evidence does.
One person or function should be accountable for the integrated value story. In larger companies this is often a value and access lead. In smaller ones it may sit with medical, access, or the program lead.
When no one owns it, functions tend to build their own versions, and payers notice the inconsistency.
At Alkemi, we help biotechnology and pharmaceutical companies define their value story early and carry it through evidence generation and access planning. We synthesize the evidence, test key assumptions with decision-makers, and align teams around a shared argument.
If you're in Phase 1 or Phase 2, planning your pivotal trial, and want to check that your evidence will support the case you need
to make, let's talk.
